Kanserde Tarama ve Erken Tanı

Yıl 2017, Cilt: 9 Sayı: 4, 210 - 221, 01.12.2017

Özge Gümüşay , Gülhan Güler Avcı

Öz

Kanserde
tarama asemptomatik bireylerde kanser ve öncül lezyonların erken saptanması ile
morbidite ve mortalitenin azaltılması için uygulanmaktadır. Tarama testi
tanısal olması şart olmayıp kanser varlığını düşündürmesi gereklidir.Yapılan çalışmalarda
serviks, kolorektal ve meme kanseri için ortalama riskli bireylerde belirli
yaşlarda uygulanan taramanın faydalı olduğu gösterilmiştir.  Bu derlemede dünyada ve Türkiye’de uygulanan
kanser tarama modaliteleri anlatılacaktır.

Anahtar Kelimeler

Kanserde tarama, mamografi, Pap smear, kolonoskopi, mortalite

Cancer Screening and Early Detection

Öz

Cancer
screening is applied to detect cancer and its precursors early in asymptomatic
individuals, with the goal of decreasing morbidity and mortality. A screening
test is not typically diagnostic for cancer, rather, it determines whether
cancer may be present. Results from well-designed studies screening for cervix,
colorectal, and breast cancers is beneficial at certain ages for people at
average risk. This article presents a summary of basic principles of cancer
screening modality across the world and Turkey.

Anahtar Kelimeler

Cancer screening, mammography, Pap smear, colonoscopy, mortality

Kaynakça

• 1. ASCO-SEP Medical Oncology Self-Evalution Program Fifth Edition (2016), Chapter 1: Epidemiology and Prevention, Page 15-17, ISBN: 978-0-9906726-3-0.
• 2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0. IARC CancerBase No. 11
• 3. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. . The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-4.
• 4. Barry H. Breast self examination does not reduce mortality. Am Fam Physician. 2003;67:1784.
• 5. US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716-26.
• 6. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al.;American Cancer Society. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614.
• 7. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603-7.
• 8. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al.; SCORE Working Group. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst. 2011;103(17):1310-22.
• 9. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al.; PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345-57.
• 10. Neugut AI, Lebwohl B. Colonoscopy vs sigmoidoscopy screening: getting it right. JAMA. 2010;304(4):461-2.
• 11. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012 May-Jun;62(3):147-72.
• 12. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103(2):304-9.
• 13. Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax. 2003;58(9):784-9.
• 14. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. PLCO Project Team. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865-73.
• 15. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
• 16. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med. 2013;159(6):411-420.
• 17. Siegel RL, Miller KD, Jemal A.Cancer statistics, 2015. A Cancer J Clin. 2015;65(1):5-29.
• 18. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9.
• 19. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8.
• 20. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-34.
• 21. Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, et al. Trivandrum Oral Cancer Screening Study Group. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005;365(9475):1927-33.
• 22. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 200l;130(7):417-22.
• 23. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu Kanser Tarama programları (http://kanser.gov.tr/kanser/kanser-taramalari, 12/2017’de erişildi.)